Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Next Previous
Search
Trial Profile

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ritlecitinib (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEGRO-2b/3
  • Sponsors Pfizer

Most Recent Events

  • 01 Apr 2025 Results (n=186) a subgroup analysis assessing the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). published in the Journal of Dermatology
  • 01 Mar 2025 Results assessing benefit-risk profile of two doses of ritlecitinib 50mg and 30 mg evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib, published in the Journal of Dermatology
  • 01 Nov 2023 Results of subgroup analysis (n=105 adolescents ) evaluating the efficacy and safety of ritlecitinib, published in the Pediatric Dermatology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top